Influence of Schistosomiasis on Fibrosis Evolution After Interferon‐Induced SVR in Chronic HCV Over a 12‐Year Biopsy‐Based Study
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.70974 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Mohamed Elbasiony und 7 weiteren Autor:innen. Beteiligte Einrichtung: Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Schistosomiasis, Liver Cirrhosis, Interferons. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Schistosomiasis ranks as the second most significant parasitic illness in terms of socioeconomic impact, after malaria. The hepatitis C virus (HCV) is a primary cause of serious liver disease, such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Schistosomiasis increases the probability of HCV co‐infection, exacerbates liver damage, and reduces the efficacy of antiviral treatments. The study aimed to compare the prognostic significance of serologically identified versus biopsy‐confirmed hepatic schistosomiasis (bilharzial hepatic granuloma) in chronic HCV patients treated with interferon‐based therapy. A cohort of 453 patients with chronic HCV who received interferon‐based therapy was followed over 12 years. Baseline assessments included clinical and laboratory tests, transient elastography, indirect hemagglutination assay (IHA) for Schistosoma antibodies, and liver biopsy. Outcomes were monitored through periodic clinical, laboratory, and elastography evaluations. fibrosis progression occurred in 50% (4/8) of patients with hepatic granulomas, while 50% demonstrated a stable course; no regression was observed. Fibrosis outcomes did not differ significantly between patients with low versus high indirect hemagglutination assay (IHA) titers. No mortality or episodes of hepatic decompensation were recorded in either group. Notably, HCC developed exclusively in the high IHA titer group (incidence rate: 0.08 per 100 person‐years). Liver Biopsy‐confirmed schistosomiasis granuloma exacerbates fibrosis outcomes in interferon‐treated chronic HCV patients. Additionally, a high Schistosoma antibody titer (IHA) is linked to increased HCC incidence, underscoring the prognostic value of both biopsy and serologic evaluation in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.
- Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
- Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Higher Technological Institute of Applied Health Science, Sherbin, Egypt.
- Tropical Medicine Department, Faculty of Medicine, Port Said University, Port Said, Egypt.
ORCID-Profile: Mohamed Elbasiony, Mohamed Abdel-Samiee, Ayman Hassan, Eman Abdelsameea, Gamal Shiha, Riham Soliman
Zitieren
APA
Elbasiony, M., Abdel-Samiee, M., Zalata, K., Hassan, A., Farahat, A., Abdelsameea, E., Shiha, G., & Soliman, R. (2026). Influence of Schistosomiasis on Fibrosis Evolution After Interferon‐Induced SVR in Chronic HCV Over a 12‐Year Biopsy‐Based Study. Journal of Medical Virology. https://doi.org/10.1002/jmv.70974
Vancouver
Elbasiony M, Abdel-Samiee M, Zalata K, Hassan A, Farahat A, Abdelsameea E, et al. Influence of Schistosomiasis on Fibrosis Evolution After Interferon‐Induced SVR in Chronic HCV Over a 12‐Year Biopsy‐Based Study. Journal of Medical Virology. 2026. doi:10.1002/jmv.70974
BibTeX
@article{Elbasiony2026,
author = {Elbasiony, Mohamed and Abdel-Samiee, Mohamed and Zalata, Khaled and Hassan, Ayman and Farahat, Ahmed and Abdelsameea, Eman and Shiha, Gamal and Soliman, Riham},
title = {Influence of Schistosomiasis on Fibrosis Evolution After Interferon‐Induced SVR in Chronic HCV Over a 12‐Year Biopsy‐Based Study},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.70974}
}
EUVIMED